Phase 1/2 study of oral GSK5460025 alone or with other anticancer agents in dMMR/MSI-H solid tumors

Phase 2, open-label trial of GSK5460025 in Nonhematologic neoplasms, colorectal cancer (CRC) and endometrial cancer (EC) (2 arms), sponsored by GSK. Primary endpoints: Number of participants with dose limiting toxicities per dose level, Number of participants with treatment emergent serious adverse events and treatment emergent adverse events by severity per dose level and 4 more. Planned start Jun 2026; status: authorised.